SO
CLDX icon

STRS Ohio’s Celldex Therapeutics CLDX Stock Holding History

STRS Ohio’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476K Buy
+12,800
New +$413K ﹤0.01% 1179
2025
Q4 		– Sell
-2,900
Closed -$75K – 2195
2025
Q3 		$75K Buy
+2,900
New +$67.2K ﹤0.01% 1916
2024
Q3 		– Sell
-6,600
Closed -$244K – 1986
2024
Q2 		$244K Buy
6,600
+700
+12% +$26.4K ﹤0.01% 1507
2024
Q1 		$247K Buy
5,900
+3,200
+119% +$131K ﹤0.01% 1497
2023
Q4 		$107K Buy
2,700
+1,300
+93% +$38.2K ﹤0.01% 1686
2023
Q3 		$38K Sell
1,400
-5,100
-78% -$160K ﹤0.01% 1823
2023
Q2 		$220K Buy
6,500
+500
+8% +$16.9K ﹤0.01% 1571
2023
Q1 		$215K Buy
6,000
+4,800
+400% +$207K ﹤0.01% 1582
2022
Q4 		$53K Buy
+1,200
New +$42.8K ﹤0.01% 1801
2022
Q1 		– Sell
-6,300
Closed -$243K – 2154
2021
Q4 		$243K Hold
6,300
– – ﹤0.01% 1678
2021
Q3 		$340K Buy
+6,300
New +$296K ﹤0.01% 1627
2015
Q3 		– Sell
-553
Closed -$157K – 1890
2015
Q2 		$209K Sell
553
-174
-24% -$69.1K ﹤0.01% 1551
2015
Q1 		$303K Buy
+727
New +$260K ﹤0.01% 1355
2014
Q2 		– Sell
-1,013
Closed -$269K – 1702
2014
Q1 		$269K Hold
1,013
– – ﹤0.01% 1355
2013
Q4 		$368K Sell
1,013
-114
-10% -$43.9K ﹤0.01% 1282
2013
Q3 		$599K Buy
1,127
+680
+152% +$233K ﹤0.01% 1148
2013
Q2 		$105K Buy
+447
New +$88K ﹤0.01% 1623

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

STRS Ohio's CLDX Position: Q2 2026 in Review

STRS Ohio opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 12,800 shares worth $476K. The stake represents ﹤0.01% of the portfolio and ranks #1179 among its holdings. This is a return to the name: STRS Ohio previously reported a position in CLDX as recently as Q3 2025.

STRS Ohio first reported a position in CLDX in Q2 2013 and has held it in 17 quarters since. The position peaked at $599K in Q3 2013. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • STRS Ohio held 12,800 shares of Celldex Therapeutics worth $476K as of Q2 2026.
  • Celldex Therapeutics was a new STRS Ohio position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1179 holding.
  • STRS Ohio first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 17 quarters since.
  • STRS Ohio's Celldex Therapeutics position peaked at $599K in Q3 2013.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.